Previously, gene mutations in BRAF within the MAPK pathway and SMO within the non-MAPK pathway in ameloblastoma have been identified.2 , 3 These findings are very important to understand ameloblastoma and for the development of new molecular targeted therapies. This evidence concerns the gene SMO and ameloblastoma.